China's Trastuzumab Rezetecan: A Breakthrough in Treating HER2-Mutant Lung Cancer Trastuzumab rezetecan secures NMPA approval as China's first domestically developed ADC, offering new hope for HER2-mutant non-small cell lung cancer patients.

China's Trastuzumab Rezetecan: A Breakthrough in Treating HER2-Mutant Lung Cancer #China #Shanghai #Hengrui_Pharma #Trastuzumab #HER2_Mutant